Tonix Pharmaceuticals Constructs Vaccine Research and Manufacturing Center

Published 9-24-2021
  • Tonix Pharmaceuticals - Advanced Development Center
  • Tonix Pharmaceuticals - Advanced Development Center

    Courtesy of IPS.

Tonix Pharmaceuticals broke ground in August of 2021 on the 45,000-sf Advanced Development Center in Dartmouth, Mass. Enabling the production of clinical-stage vaccines for COVID-19 and other infectious diseases, the BSL-2 facility will utilize single-use bioreactors and purification suites for optimal efficiency and flexibility. The cGMP center will also offer state-of-the-art research, development, and analytical suites. Approximately 70 scientists, technicians, and manufacturing staff will work in the turnkey building. 

The fast-tracked development includes renovation of an existing 40,000-sf structure in the New Bedford Business Park and construction of a 4,000-sf addition. Design-build contractor The Cardinal Group and engineering firm IPS are leveraging an integrated project delivery approach to accelerate the construction timeline so that operations can commence in spring of 2022.

Related Organizations
Engineer of Record
IPS